Quince Therapeutics (QNCX) CEO granted 1M stock options

Rhea-AI Filing Summary

Quince Therapeutics CEO and CMO Dirk Thye reported a new stock option grant. On January 23, 2026, he was granted an employee stock option to buy 1,000,000 shares of Quince Therapeutics common stock at an exercise price of $3.08 per share.

The filing shows Thye directly holds 1,000,000 derivative securities after this grant. The option vests in 48 equal monthly installments, with 1/48 vesting on the grant date and the remaining portions vesting on the first day of each subsequent month, so the award is scheduled to be fully vested by December 1, 2029.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thye Dirk

(Last) (First) (Middle)

C/O QUINCE THERAPEUTICS, INC.

611 GATEWAY BLVD., SUITE 273

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Quince Therapeutics, Inc. [ QNCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and CMO

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$3.08	01/23/2026		A		1,000,000		(1)	01/23/2036	Common Shares	1,000,000	$0	1,000,000	D

Explanation of Responses:

1. The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting with 1/48th vesting on the date of grant and the remaining options vesting on the 1st day of each subsequent month, such that the total number of shares shall be fully vested on December 1, 2029.

	/s/ Brendan Hannah as attorney-in-fact for Dirk Thye	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Quince Therapeutics (QNCX) CEO Dirk Thye report on this Form 4?

Dirk Thye reported receiving an employee stock option grant covering 1,000,000 shares of Quince Therapeutics common stock.

What is the exercise price of the new Quince Therapeutics (QNCX) stock options?

The employee stock option grant has an exercise price of $3.08 per share for Quince Therapeutics common stock.

When do Dirk Thye’s Quince Therapeutics (QNCX) options vest?

The options vest in 48 equal monthly installments, with 1/48 vesting on the grant date and the rest on the first day of each month until they are fully vested on December 1, 2029.

How many Quince Therapeutics (QNCX) derivative securities does Dirk Thye hold after this transaction?

After the reported grant, Dirk Thye beneficially owns 1,000,000 derivative securities related to this employee stock option.

What is Dirk Thye’s role at Quince Therapeutics (QNCX) according to the filing?

According to the filing, Dirk Thye is both a director and an officer of Quince Therapeutics, serving as CEO and CMO.

Is the Quince Therapeutics (QNCX) option grant to Dirk Thye a direct holding?

Yes. The Form 4 indicates the 1,000,000 stock options are held as a direct ownership position.